Peptide Therapeutics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Peptide Therapeutics Market Trends and Insights

Rising Prevalence of Cancer & Metabolic Diseases

Oncology and metabolic disorders increasingly share a therapeutic toolbox, as peptide receptor radionuclide therapy and GLP-1 agonists demonstrate disease-modifying potential across both areas. FDA approval of elamipretide for Barth syndrome and ongoing expansion of PRRT validate peptides in rare cancers where small molecules lack specificity^{[1]U.S. FDA, “47 Peptide Candidates Granted Orphan Status in 2024,” fda.gov}. Dual agonists such as tirzepatide reduced HbA1c by up to 2.59% and delivered weight loss in 88% of Phase 3 patients, moving peptides toward first-line use in type 2 diabetes. Computational biology is widening the discovery funnel; the 2025 Peptide Predictor algorithm uncovered BRP, an anti-obesity peptide beyond the incretin axis. Peptides now represent 18% of global Phase 2/3 pipelines, and Novo Nordisk’s REDEFINE 1 results with CagriSema further underscore multi-factor risk reduction in cardiometabolic disease. These clinical wins are redirecting R&D budgets away from small molecules and bolstering long-term demand for the peptide therapeutics market.

Surge in Big-Pharma Funding for GLP-1 & Multi-Agonist Pipelines

Record-breaking transactions highlight how pharmaceutical leaders treat peptides as defensive assets against looming patent cliffs. Zealand Pharma’s USD 1.65 billion upfront deal with Roche values petrelintide at 12 times the company’s 2024 revenue. Novo Nordisk’s USD 285 million TransCon Semaglutide partnership shows innovators paying for monthly dosing regimens expected to win formulary preference. PeptiDream’s USD 180 million Novartis pact for radioligand conjugates proved that early discovery platforms can now fetch late-stage multiples. Earlier-stage collaborations, including a USD 1 billion Genentech agreement for peptide-RNAi conjugates, signal that capital is flowing across the development continuum. As acquisition timelines compress, smaller biotech firms with validated peptide libraries can achieve premium valuations quickly, a pattern that supports sustained expansion of the peptide therapeutics market.

Maturing Solid-Phase & Hybrid Synthesis Platforms

Industry adoption of continuous-flow SPPS and hybrid liquid-phase routes is cutting process mass intensity by up to 50%, meeting investor and regulator expectations for greener manufacturing. Enzymatic synthesis eliminates protecting groups but remains limited to short sequences, whereas hybrid SPPS-LPPS and flow reactors already support peptides exceeding 50 amino acids at Lonza and Bachem sites. FDA guidance released in 2024 formally accepts continuous manufacturing for peptide APIs, accelerating CDMO investment in advanced reactors. Generic players benefit most, as optimized SPPS reduced Hikma’s liraglutide API cost by 35% versus the innovator process^{[3]Hikma, “Generic Liraglutide Approval,” hikma.com}. These efficiencies enable competitive pricing in the peptide therapeutics market without eroding margins.

Regulatory Fast-Track Pathways for Rare-Disease Peptides

Accelerated approval programs in the United States, Europe, and Japan are shrinking timelines for rare-disease peptide therapies. The FDA granted orphan-drug status to 47 peptide candidates in 2024, up from 32 in 2023, underscoring a growing focus on conditions that affect fewer than 200,000 U.S. patients. Commercial viability was highlighted when elamipretide won approval for Barth syndrome, an ultra-rare disorder with roughly 300 patients, and payers accepted annual treatment costs above USD 500,000. In Europe, the EMA’s PRIME scheme fast-tracked 12 peptide programs in 2024, cutting Phase 3 study durations by about nine months. Japan’s PMDA introduced a 2024 conditional pathway that allows marketing based on Phase 2 data, a route already used by PeptiDream and Takeda. Collectively, these mechanisms let developers earn revenue sooner, finance process optimization, and later pursue broader labels once initial approvals are secured.

Proteolytic Instability & Low Oral Bioavailability

Peptides are naturally susceptible to enzymatic degradation, restricting viable oral candidates to a narrow subset. Novo Nordisk’s Rybelsus achieves just 1% bioavailability and requires a 14 mg dose to match a 1 mg injection. Mycapssa’s TPE-enabled oral octreotide reaches 0.9% bioavailability and still needs twice-daily dosing. Device-based solutions like the RaniPill mechanically inject the drug into the intestinal wall but introduce manufacturing and patient-acceptance hurdles. Formulation enhancers add up to 50% in development cost and extend clinical timelines by as much as 18 months. Consequently, oral delivery remains a meaningful yet capped opportunity within the peptide therapeutics market.

High cGMP Manufacturing Cost vs. Small-Molecule APIs

A kilogram of cGMP peptide API can cost three to five times more than a small-molecule equivalent, largely due to a process mass intensity near 13,000 kg waste per kg of product^{[2]Royal Society of Chemistry, “Process Mass Intensity of SPPS,” rsc.org}. EMA’s 2025 guideline now requires impurity profiling down to 0.05% for long peptides, adding up to USD 100,000 per batch in QC costs. Recombinant expression can deliver 50% savings for peptides longer than 40 amino acids, but its applicability is limited by host folding constraints. The 2025 shortage of Wang and 2-chlorotrityl resins raised raw-material prices by 40%, further squeezing CDMO margins. These economic pressures restrict broad generic penetration and confine the peptide therapeutics industry to indications that support premium pricing.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Marketing Type: Generics Capitalize on Patent Expiry

The peptide therapeutics market for branded peptides in 2025 represented a 61.55% share. Branded incumbents defend position through lifecycle strategies such as Novo Nordisk’s TransCon Semaglutide collaboration and Roche’s acquisition of petrelintide rights. Generic formulations, however, are projected to grow at an 8.25% CAGR from 2026 to 2031, buoyed by the FDA approval of generic liraglutide and a pipeline of ANDAs for exenatide and dulaglutide. 

Generic manufacturers face higher comparability burdens because bioequivalence studies cost USD 5-10 million and SPPS batch variability challenges validation. Yet companies like Biocon and Dr. Reddy’s leverage recombinant expression to price biosimilar insulins 15-30% below reference brands while staying profitable, reinforcing momentum in the generic sub-segment of the peptide therapeutics market.

By Application: Gastrointestinal Peptides Accelerate

Oncology maintained 35.53% peptide therapeutics market share in 2025 on the back of PRRT products such as Lutathera, but GI disorders will expand at an 11.85% CAGR through 2031. Takeda’s USD 900 million acquisition of apraglutide and Zealand Pharma’s ongoing glepaglutide program illustrate strong sponsor appetite for GLP-2 analogs in short bowel syndrome. 

Teduglutide’s USD 450 million 2024 sales verify commercial viability, while follow-on dual GLP-1/GLP-2 candidates are advancing for inflammatory bowel disease. Elsewhere, peptide vaccines such as SELLAS’s galinpepimut-S reach Phase 3 in leukemia, highlighting oncology’s innovation depth even as its growth rate moderates.

By Route of Administration: Oral Delivery Gains Traction

Parenteral injections commanded 80.63% of 2025 volumes, ensuring reliable exposure and near-complete bioavailability. In contrast, oral formulations, led by Rybelsus, are growing at a 12.87% CAGR, signaling patient preference for needle-free dosing despite higher milligram requirements. 

Licensing demand for SNAC absorption enhancer technology and device approaches like the RaniPill show broadening interest, although only peptides with specific physicochemical profiles or mechanical delivery solutions can cross the oral viability threshold. This duality will persist as an innovation hotspot in the peptide therapeutics market.

By Technology: Recombinant Expression Scales Up

Solid-phase peptide synthesis contributed 45.13% of the peptide therapeutics market size in 2025, but recombinant expression is advancing at a 13.7% CAGR, reflecting 30–50% lower cost-of-goods for long sequences. E. coli and Pichia pastoris remain the dominant hosts, while CHO systems handle peptides needing post-translational modifications. 

Continuous-flow SPPS and hybrid LPPS-SPPS processes cut waste by 40–50%, yet capital intensity keeps adoption concentrated among major CDMOs. Enzymatic synthesis is promising but remains pre-commercial due to enzyme specificity limits.

By End User: Innovators Internalize Early Development

Hospitals and clinics held 42.24% revenue in 2025, anchored by injectable products requiring professional administration. Pharmaceutical and biotech companies are the fastest-growing end users at a 12.51% CAGR, as firms like Novartis and Eli Lilly bolster internal peptide chemistry to shorten lead optimization cycles. 

Academic institutes benefit from AI tools such as the PepMimic algorithm, which lower discovery barriers, spawning university spinouts that may license or self-develop candidates, thereby broadening the stakeholder base within the peptide therapeutics industry.

Geography Analysis

North America held 38.34% share in 2025, propelled by FDA fast-track designations and a 25% manufacturing tax credit that supported Lonza’s USD 475 million Portsmouth plant and Bachem’s USD 190 million Vista facility. The United States captures roughly 70% of regional revenue given payer tolerance for annual therapy costs above USD 10,000. Canada and Mexico add mid-single-digit contributions, with Mexico playing a nearshoring role for API production aimed at U.S. demand. 

Asia-Pacific is the fastest-growing region, registering a 12.81% CAGR through 2031. China’s accelerated pathways enabled domestic GLP-1 biosimilar launches, and WuXi Biologics expanded fermentation capacity by 5,000 liters in 2024. India’s Biocon and Dr. Reddy’s exploit recombinant expression for insulin analogs sold across Europe and Southeast Asia, while Japan’s PeptiDream underpins regional innovation with trillion-member peptide libraries. South Korea and Australia contribute emerging CDMO and reimbursement opportunities. 

Growth in Europe is moderated by the EMA’s 2025 impurity guideline, which elevated QC costs by up to USD 100,000 per batch. Germany leads regional production through PolyPeptide’s USD 150 million expansion, yet labor and energy costs remain 20–30% higher than Asia-Pacific. PRIME designations for 12 peptide programs in 2024 shorten European timelines, but manufacturers shoulder added compliance spending, tempering regional CAGR.

Regulatory Landscape

Regulatory requirements for peptide therapeutics are tightening around CMC controls, impurity characterization, and clinical pharmacology expectations across major markets. In the European Union, the European Medicines Agency (EMA) Guideline on the Development and Manufacture of Synthetic Peptides became effective on June 1, 2026. It sets more explicit expectations for manufacturing, characterization, specifications, and analytical controls, including reporting, identification, and qualification thresholds for peptide-related impurities.

In the United States, the FDA keeps peptide-specific development expectations in view through its Clinical Pharmacology Considerations for Peptide Drug Products guidance, while compounding oversight remains an active topic for peptide bulk drug substances. The FDA scheduled a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 to evaluate seven peptide bulk drug substances for potential inclusion on the 503A list, which reinforces the importance of clear regulatory positioning between compounded supply and approved peptide drug pathways.

Market Opportunities and Future Outlook

CDMO and API capacity expansion remains a key whitespace across geographies, particularly as demand concentrates in high-volume peptide categories such as GLP-1 and longer, complex sequences that increase pressure on SPPS throughput, purification, and release testing. 2026 announcements show multi-region buildout, including AmbioPharm's 68,000-square-foot expansion in North Augusta, South Carolina (March 2026) for flexible SPPS, LPPS, and hybrid synthesis, Lupin Manufacturing Solutions' Dabhasa, India expansion (March 2026) to scale peptide building blocks and CRDMO capabilities, and Space Peptides (Taizhou) approving an equity investment (April 2026) to lift annual SPPS capacity to over 70,000 liters and annual output to more than 30 tons. Larger, longer-horizon investments also reinforce the pipeline-to-supply linkage, such as Eli Lilly's USD 6 billion API facility announcement in Huntsville, Alabama (December 2025) and CordenPharma starting a greater than EUR 500 million greenfield peptide facility program in Muttenz, Switzerland (March 2025) designed for SPPS reactor capacity exceeding 5,000 liters.

Follow-on and lifecycle strategies broaden the opportunity around analytical differentiation, impurity control, and comparability packages for 505(j) and 505(b)(2) pathways, where peptide-specific immunogenicity and impurity qualification remain gating items. FDA-CDER-2026-0083, an FDA research effort to determine qualification limits for peptide-related impurities of follow-on products, points to an increased focus on immunogenicity-linked impurity thresholds, driving demand for advanced characterization, orthogonal analytics, and robust control strategies. It also supports integrated service models (API, analytical development, and in some cases adjacent modalities) as sponsors seek fewer handoffs from late-stage to commercial supply.